CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy
Duk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahn
Cancer Research and Treatment. 2006;38(4):201-205.   Published online 2006 December 31    DOI: https://doi.org/10.4143/crt.2006.38.4.201

Excel Download

Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy
Cancer Research and Treatment. 2006;38(4):201   Crossref logo
Link1 Link2

Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line Therapy
Cancer Research and Treatment. 2004;36(4):235   Crossref logo
Link1 Link2

Phase II Trial of 5-Fluorouracil/Leucovorin/Gemcitabine/Cisplatin as Second-Line Treatment in Patients with Metastatic or Recurrent Colorectal Carcinoma: A Cancer Therapeutics Research Group Study
Clinical Colorectal Cancer. 2007;6(9):646-651   Crossref logo
Link1 Link2

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
BMC Cancer. 2007;7(1):   Crossref logo
Link1 Link2 Link3

A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer
Clinical Colorectal Cancer. 2010;9(3):157-161   Crossref logo
Link1 Link2

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
OncoTargets and Therapy. 2015;1061   Crossref logo
Link1

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
European Journal of Cancer. 1999;35(9):1338-1342   Crossref logo
Link1 Link2

740 POSTER Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy in patients with advanced gastric cancer —interim analysis of a multicenter, randomized phase II trial
European Journal of Cancer Supplements. 2005;3(2):211-212   Crossref logo
Link1 Link2

A Phase II Study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and ironotecan in the treatment of metastatic colorectal cancer patients
European Journal of Cancer. 2002;38:S72   Crossref logo
Link1 Link2

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
Annals of Oncology. 2004;15(12):1766-1772   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.